Betty Chang
Corporate Officer/Principal presso SUMMIT THERAPEUTICS INC.
Profilo
Betty Chang is currently the Head of Research, Oncology & Inflammation at Summit Therapeutics, Inc. She previously worked as an Associate Director at Rigel Pharmaceuticals, Inc. from 2004 to 2009.
In 2009, she briefly held the position of Associate Director at Lundbeck Seattle BioPharmaceuticals, Inc. From 2009 to 2018, she served as the Vice President of Research & Biology at Pharmacyclics LLC.
In 2018 and 2019, she was the Chief Operating Officer & EVP-Product Development at Angarus Therapeutics, Inc. Most recently, from 2020 to 2021, she worked as the Senior Vice President of Translational Research at Molecular Templates, Inc. Dr. Chang holds a doctorate degree from the University of California, Davis.
Posizioni attive di Betty Chang
| Società | Posizione | Inizio |
|---|---|---|
| SUMMIT THERAPEUTICS INC. | Corporate Officer/Principal | 01/06/2021 |
Precedenti posizioni note di Betty Chang
| Società | Posizione | Fine |
|---|---|---|
| MOLECULAR TEMPLATES, INC. | Corporate Officer/Principal | 01/06/2021 |
Angarus Therapeutics, Inc.
 Angarus Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Angarus Therapeutics, Inc. engages in the development of immuno-oncology therapies. It specializes in modulating the tumor microenvironment by activating innate immunity. The company was founded by Ling Yin Li, Chih Ping Liu, and Mark Smith and is headquartered in Sunnyvale, CA. | Direttore operativo | 01/01/2019 |
| PHARMACYCLICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2018 |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/11/2009 |
| RIGEL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2009 |
Formazione di Betty Chang
| University of California, Davis | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| SUMMIT THERAPEUTICS INC. | Health Technology |
| MOLECULAR TEMPLATES, INC. | Health Technology |
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Angarus Therapeutics, Inc.
Angarus Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Angarus Therapeutics, Inc. engages in the development of immuno-oncology therapies. It specializes in modulating the tumor microenvironment by activating innate immunity. The company was founded by Ling Yin Li, Chih Ping Liu, and Mark Smith and is headquartered in Sunnyvale, CA. | Health Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Borsa valori
- Insiders
- Betty Chang
